370 related articles for article (PubMed ID: 9057854)
1. Structure-based design of substituted diphenyl sulfones and sulfoxides as lipophilic inhibitors of thymidylate synthase.
Jones TR; Webber SE; Varney MD; Reddy MR; Lewis KK; Kathardekar V; Mazdiyasni H; Deal J; Nguyen D; Welsh KM; Webber S; Johnston A; Matthews DA; Smith WW; Janson CA; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Bartlett CA; Morse CA
J Med Chem; 1997 Feb; 40(5):677-83. PubMed ID: 9057854
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
[TBL] [Abstract][Full Text] [Related]
3. Quinazoline antifolates thymidylate synthase inhibitors: lipophilic analogues with modification to the C2-methyl substituent.
Hennequin LF; Boyle FT; Wardleworth JM; Marsham PR; Kimbell R; Jackman AL
J Med Chem; 1996 Feb; 39(3):695-704. PubMed ID: 8576912
[TBL] [Abstract][Full Text] [Related]
4. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
Springer CJ; Bavetsias V; Jackman AL; Boyle FT; Marshall D; Pedley RB; Bisset GM
Anticancer Drug Des; 1996 Dec; 11(8):625-36. PubMed ID: 9022750
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
Gangjee A; Lin X; Kisliuk RL; McGuire JJ
J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
[TBL] [Abstract][Full Text] [Related]
7. Potent inhibition of thymidylate synthase by two series of nonclassical quinazolines.
McNamara DJ; Berman EM; Fry DW; Werbel LM
J Med Chem; 1990 Jul; 33(7):2045-51. PubMed ID: 2362285
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of 9-acridinyl sulfur derivatives: sulfides, sulfoxides and sulfones. Comparison of their activity on tumour cells.
Santelli-Rouvier C; Barret JM; Farrell CM; Sharples D; Hill BT; Barbe J
Eur J Med Chem; 2004 Dec; 39(12):1029-38. PubMed ID: 15571864
[TBL] [Abstract][Full Text] [Related]
9. Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
Gangjee A; Jain HD; McGuire JJ; Kisliuk RL
J Med Chem; 2004 Dec; 47(27):6730-9. PubMed ID: 15615522
[TBL] [Abstract][Full Text] [Related]
10. Quinazoline antifolate thymidylate synthase inhibitors: gamma-linked L-D, D-D, and D-L dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Bavetsias V; Jackman AL; Kimbell R; Gibson W; Boyle FT; Bisset GM
J Med Chem; 1996 Jan; 39(1):73-85. PubMed ID: 8568829
[TBL] [Abstract][Full Text] [Related]
11. Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series.
Marsham PR; Jackman AL; Barker AJ; Boyle FT; Pegg SJ; Wardleworth JM; Kimbell R; O'Connor BM; Calvert AH; Hughes LR
J Med Chem; 1995 Mar; 38(6):994-1004. PubMed ID: 7699716
[TBL] [Abstract][Full Text] [Related]
12. High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
Kuyper LF; Baccanari DP; Jones ML; Hunter RN; Tansik RL; Joyner SS; Boytos CM; Rudolph SK; Knick V; Wilson HR; Caddell JM; Friedman HS; Comley JC; Stables JN
J Med Chem; 1996 Feb; 39(4):892-903. PubMed ID: 8632413
[TBL] [Abstract][Full Text] [Related]
13. Folate-based inhibitors of thymidylate synthase: synthesis and antitumor activity of gamma-linked sterically hindered dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Bavetsias V; Jackman AL; Marriott JH; Kimbell R; Gibson W; Boyle FT; Bisset GM
J Med Chem; 1997 May; 40(10):1495-510. PubMed ID: 9154971
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents.
Chern JW; Leu YL; Wang SS; Jou R; Lee CF; Tsou PC; Hsu SC; Liaw YC; Lin HM
J Med Chem; 1997 Jul; 40(14):2276-86. PubMed ID: 9216847
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
[TBL] [Abstract][Full Text] [Related]
16. Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 position.
Hughes LR; Jackman AL; Oldfield J; Smith RC; Burrows KD; Marsham PR; Bishop JA; Jones TR; O'Connor BM; Calvert AH
J Med Chem; 1990 Nov; 33(11):3060-7. PubMed ID: 2231606
[TBL] [Abstract][Full Text] [Related]
17. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
18. Mode of action of site-directed irreversible folate analogue inhibitors of thymidylate synthase.
Lobo AP; Nair MG; Changchien L; Weichsel A; Montfort WR; Maley F
Biochemistry; 1998 Mar; 37(13):4535-42. PubMed ID: 9521774
[TBL] [Abstract][Full Text] [Related]
19. Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.
Caturla F; Amat M; Reinoso RF; Calaf E; Warrellow G
Bioorg Med Chem Lett; 2006 Jul; 16(13):3605-8. PubMed ID: 16647258
[TBL] [Abstract][Full Text] [Related]
20. Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and polyglutamation.
Jackman AL; Kimbell R; Brown M; Brunton L; Bisset GM; Bavetsias V; Marsham P; Hughes LR; Boyle FT
Anticancer Drug Des; 1995 Oct; 10(7):573-89. PubMed ID: 7495480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
